Skip to main content

Christopher Ryan Kelsey

Professor of Radiation Oncology
Radiation Oncology
Radiation Oncology, Box 3085, Durham, NC 27710
30 Duke Medicine Circle, Room 05125A, Durham, NC 27710

Overview


I specialize in the treatment of hematologic and thoracic malignancies. I have a special research interest in optimizing radiation therapy in lymphomas and leukemias, particularly consolidation radiation therapy in diffuse large B-cell lymphoma and total body irradiation in the setting of allogeneic stem cell transplantation. Other academic interests include cardiac toxicity after radiation therapy for lung cancer and optimizing stereotactic body radiation therapy for stage I non-small cell lung cancer.

Current Duke Appointments & Affiliations


Professor of Radiation Oncology · 2020 - Present Radiation Oncology, Clinical Science Departments
Member of the Duke Cancer Institute · 2017 - Present Duke Cancer Institute, Institutes and Centers

Recent Scholarly Works


Historical outcomes for patients with stage IA NLPHL: Global NLPHL One Working Group retrospective analyses.

Journal article Blood Adv · August 11, 2026 We evaluated outcomes by management type for patients with stage IA nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) in the Global NLPHL One Working Group retrospective database of 2243 patients with stages I to IV disease diagnosed from 1992 to 202 ... Full text Link to item Cite

Safety and Efficacy of Bronchoscopic Pulsed Electric Field Ablation for Lung Cancer and Metastases.

Journal article JTO Clin Res Rep · August 2026 BACKGROUND: Local treatment options for progressive lung cancer or metastases located in the central or middle thirds of the lungs are limited, especially if progression occurs after radiation. In these patients, local thermal ablative therapies are fraugh ... Full text Link to item Cite

Infectious Complications of CD19-targeted Chimeric Antigen Receptor T-cell Therapy: a Multicenter Cohort Study.

Journal article Open Forum Infect Dis · July 2026 BACKGROUND: Our understanding of the epidemiology of and risk factors for postchimeric antigen receptor T-cell therapy (CART) infections is largely based on data from single-center studies with small sample sizes. METHODS: This is a multicenter, cohort stu ... Full text Link to item Cite
View All Scholarly Works

Recent Grants


Serum pro-N-cadherin as an early biomarker of radiation-induced heart disease

ResearchCo Investigator · Awarded by National Institutes of Health · 2025 - 2030

View All Grants

Education


University of Colorado, Denver · 2002 M.D.
Brigham Young University · 1998 B.S.